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Abstract: Since both intellectual disability and challenging behaviour are entities encompassing heterogeneous clinical 
conditions and current taxonomies are of limited use in this field of psychiatry, diagnosing psychiatric symptoms in 
intellectually disabled patients is still very complex. In the diagnostic process of psychiatric symptoms and behavioural 
abnormalities, the first step should be genome profiling using the latest techniques in order to detect pathogenic CNVs or 
single gene mutations that are causative for the developmental delay. Their importance can be derived from the scientific 
observation that several genetic syndromes are associated with a specific behavioural, psychiatric, neuropsychological 
or neurological symptom profile, relevant for both choice of treatment and prognosis. Second, it has to be stressed that 
psychiatric disorders, especially from the depression and anxiety spectrum, frequently manifest with atypical symptoms 
that may hamper adequate pharmacological treatment. With respect to challenging behaviours in general, it should be 
emphasized that these are essentially dependent on contextual variables for which no rational pharmacological 
treatment is available and behavioural interventions are primarily warranted. Prescription of psychotropics has been 
demonstrated to be marginally effective only and to induce regularly unwanted side effects or even an increase of 
abnormal behaviours. It is therefore recommended to measure always the plasma concentration of psychotropics and 
antiepileptics and to perform, preferably prior to the start of treatment, genotyping of relevant cytochrome isoenzymes. 
In is concluded that, apart from the a priori genetic analysis, careful investigation of the here described data sources is 
needed to formulate a diagnostic hypothesis and treatment proposal. 
Keywords: Psychiatric diagnosis, DSM, genetic etiology, psychotropics, pharmacogenetics, behaviour, behavioural 
phenotype.  
INTRODUCTION 
For psychiatry, genetic disorders form an intriguing 
challenge since they present a unique opportunity to 
study symptoms or symptom profiles in relation to a 
known aetiology and sometimes pathophysiology. As 
shown over the past decades, the search for candidate 
genes and copy number variations has increased the 
understanding of putative pathophysiological 
mechanisms underlying psychiatric disorders such as 
schizophrenia [1, 2], bipolar disorders [3], attention 
deficit disorder [4] and autism [5].  
For all psychiatric disorders, categorical psychiatric 
taxonomies like the Diagnostic and Statistical Manual 
(DSM) of the American Psychiatric Association are 
routinely used for diagnosing which, however, often 
results in several ‘diagnoses’ at the same time. This 
phenomenon is called comorbidity. As stated for  
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decades by several authors, such a nosological 
approach leads to diagnostic inflation with harmful side 
effects such as proliferation of new diagnoses and 
magnifying of comorbidity [6-8]. Moreover, the DSM 
system that was originally intended to create a 
common language may generate an epistemology of 
blindness that hinders the evolution of well founded 
diagnoses [9]. Finally, it should be emphasized that 
current psychiatric taxonomies are primarily tailored by 
consensus, not by empirics, and based on the 
presumption that a common pathophysiology underlies 
psychiatric categories. 
As formulated by Lyketsos and colleagues, (neuro) 
psychiatry should operate bottom-up ‘beginning with 
the emergence of pathology in the brain and attempting 
to understand the emerging of clinical syndromes out of 
this pathology’ [10]. Such a bottom-up approach also 
needs a theoretical framework because, without theory, 
categories tend to increase as is illustrated by their 
growing number in subsequent DSM-versions [11, 12]. 
Clinical syndromes that arise from such a bottom-up 
orientation are not congruent with DSM categories but 
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are reflections of a certain probability to develop a 
variety of psychiatric and neurocognitive symptoms 
[13].  
The triviality of a top-down approach is best 
illustrated by the ‘disorder’ called mental retardation or 
intellectual disability (ID) that is not a disease or a 
disability but rather an essential phenomenon in a 
heterogeneous group of clinical conditions, ranging 
from genetic disorders to infectious diseases [14, 15]. 
In case of genetic disorders, the chance to define a 
phenotype is proportional to the prevalence of the 
disorder and the research efforts on its phenomenology 
and pathophysiology [13]. The same holds for 
emerging pharmacological treatment modalities that 
will be increasingly targeted not at DSM diagnoses but 
at functional impairments related to genetics and 
genomics crossing nosological boundaries [16, 17]. 
In the following, first, main ingredients will be 
outlined for an appropriate diagnostic process of 
neurocognitive and behavioural abnormalities as well 
as psychiatric symptoms in intellectually disabled 
patients. Second, a few examples of genetic 
syndromes with their variable levels of ID and their 
specific neuropsychiatric symptom profile, course and 
putative treatment regimens will be given. Finally, some 
future vistas will be discussed. 
PHASING THE DIAGNOSTIC PROCESS 
Clarification  
In the majority of cases, challenging behaviours are 
the primary reason for psychiatric consultation [18, 19]. 
To start with, results of recent psychological data, both 
cognitive and social emotional, as well as information 
about developmental and family history have to be 
collected. Since, with the exception of mood and 
anxiety disorders, the prevalence of psychiatric 
disorders in patients with ID is comparable to that in the 
general population [20, 21], instantaneous psychiatric 
labelling should be avoided. Instead, the diagnostic 
process should first continue with a functional analysis 
of the behaviour using detailed interviewing of primary 
care givers, preferably supported by video registration 
of the patient’s behavioural repertoire. The latter can 
also be used to record phenotypical characteristics, 
especially dysmorphic features. 
Subsequently, from the behavioural repertoire, 
essential elements can be discerned and specified by 
using e.g. the Aberrant Behaviour Checklist (ABC) [22, 
23], the Diagnostic Assessment for the Severely 
Handicapped (DASH) [24, 25] and the Psychiatric 
Assessment Schedule for Adults with a Developmental 
Disability (PAS-ADD) [26, 27]. From these, cognitive 
and behavioural aspects of psychiatric disorders can 
be tentatively grouped into the symptomatic domains of 
motor activity, motivation, affect as well as thinking and 
perception [28].  
The here described initial diagnostic phase 
translates the original referral question into a more 
circumscript plan of investigative actions. 
Additional Inquiries and Hypotheses 
Here, the first step has to be the diagnostic genome 
profiling with recent techniques since submicroscopic 
rearrangements are a common cause of ID [29, 30]. In 
the past two decades, traditional karyotyping and 
molecular cytogenetic techniques such as 
fluorescence-in-situ-hybridization (FISH) and multiplex 
ligation-dependent probe amplification(MLPA), both 
with limited level of detection, have been replaced by 
array-based comparative genomic hybridization (array 
CGH) [31, 32]. Genome wide array analysis may reveal 
etiologically relevant copy number variations (CNVs) 
while diagnostic exome sequencing aims to detect 
single gene mutations [33, 34]. 
Second, detailed information about developmental 
trajectory and family history has to be collected. These 
data may reveal a relapsing or deteriorating course as 
well as family load with psychiatric diseases, in 
particular (bipolar) affective disorders. The case history 
should also include information on the use of 
medication by the mother during pregnancy e.g. 
antiepileptics that may lead to ID with accompanying 
behavioural problems and somatic comorbidities [35]. 
In general, a substantial percentage of patients with ID 
are suffering from epilepsy for which treatment with 
antiepileptics is given. Special forms of epilepsy also 
exist, as is the case with gelastic seizures in 
hypothalamic hamartomas and the specific behavioural 
disturbances which these entail such as excessive 
laughing and crying as well as aggressive outbursts 
[36]. The use of antiepileptics may also give rise to 
behavioural and psychiatric symptoms e.g. psychosis-
inducing properties of levetiracetam and topiramate as 
well as confusional states induced by benzodiazepines 
[37]. Furthermore, it should be stressed that epileptic 
seizures are frequently associated with psychoses, 
both post- and interictal, and mood disorders [38] and 
that there exists an array of potential risk factors for 
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ictally related psychoses, such as early age at epilepsy 
onset, history of prolonged febrile convulsions, and 
intellectual disability [39]. 
Moreover, since virtually no information exits about 
the bioavailability of psychotropics in patients with ID, 
measurement of plasma concentrations and 
identification of genetic polymorphisms of cytochromes 
P450 is strongly recommended [40, 41], especially in 
case of antiepileptic co-medication. Finally, it should be 
stressed that, in ID patients, a great variety of physical, 
medical and contextual conditions may present with 
behavioural problems only [42, 43]. 
With respect to the manifestation of psychiatric 
symptoms in ID patients, one should constantly be 
aware of atypical phenomena, in that e.g. depression 
frequently presents with a disturbed regulation of 
aggression and that episodic alterations of mood and 
behaviour which do not meet the criteria for bipolar 
disorder or cyclothymia, occur regularly [44] and should 
therefore be termed unstable mood disorder [45]. 
For the purpose of diagnostic hypothesis 
formulation, it should be underlined that ID and other 
brain disorders obviously affect the development of 
interpersonal contact and social as well as language 
skills, with lower levels of intellectual functioning 
generally associated with higher incidence of 
interpersonal contact problems. In ID populations, 
autism spectrum disorder (ASD) and attention deficit 
hyperactivity disorder (ADHD) are often wrongly 
classified since these ‘diagnoses’ are typically based 
on DSM-criteria without providing information regarding 
aetiology [46, 47]. 
Clinical Decision Making  
Based on all available data from the former phases 
complemented by information from most recent 
literature, a psychiatric diagnosis may be formulated in 
one of the following forms: (a) classic psychiatric 
disorder with or without an atypical symptom profile 
[21]; (b) syndrome-specific psychiatric disorder e.g. 
bipolar disorder in Prader-Willi syndrome [48]; (c) 
psychiatric disorder related to underlying somatic/ 
neurological suffering e.g. cognitive-affective syndrome 
in Charlevoix-Saguenay ataxia [49]; (d) disinhibited 
behaviours due to environmental factors; or (e) drug-
related behavioural disorders. In case a genetic 
syndrome is associated with a specific cognitive, 
neurological or psychiatric profile, the term psycho-
pathological or, more specific, neuropsychological, 
neurological or (neuro) psychiatric phenotype, can best 
be used. Once a diagnosis has been made, mostly, a 
targeted and personalized treatment design can be 
formulated. 
PSYCHOPATHOLOGICAL PHENOTYPES: SOME 
EXAMPLES  
22q11.2 Microdeletion (22q11.2DS;OMIM:192430) 
This is the most common microdeletion syndrome 
formerly called Velo-Cardio-Facial Syndrome, with a 
highly variable phenotype. Its behavioural phenotype, 
including the psychopathological features and 
endocrine dysfunctions, especially hypoparathyroidism, 
was originally described by the speech therapist Robert 
Shprintzen [50]. Over subsequent years it became 
apparent that 22q11DS is highly associated with 
symptoms from the schizophrenia, bipolar, anxiety and 
autistic spectrum [51, 52]. With respect to the 
neuropsychological phenotype, it has been shown that 
deficits in problem solving and planning as well as in 
abstract and social thinking are most prominent [53]. It 
has to be stressed, however, that psychiatric symptoms 
from the affective, obsessive-compulsive and psychotic 
domains originate from the discrepant intellectual 
profile and impaired visuoperceptual abilities with a 
diminished comprehension of abstract and symbolic 
language [54]. Although Schneider and co-workers 
recently mentioned the persistence of negative 
psychotic symptoms in 22q11DS [55], it should be 
underlined that these phenomena may also stem from 
the neurocognitive dysfunctions. 
Apart from the above mentioned neuropsychiatric 
and neuropsychological sequellae, it has become 
obvious that the 22q11.2 microdeletion syndrome, from 
approximately the age of forty, shows, in a minority of 
cases, a deteriorating course with Parkinsonian 
symptoms [56, 57]. 
Concerning the treatment regimen, a distinction 
should be made between pharmacological and non-
pharmacological strategies. First, of course, endocrine 
dysfunctions have to be corrected since they may 
mimic psychotic features. Second, it has been 
repeatedly demonstrated that psychotic symptoms in 
22q11.2DS do not respond to classical antipsychotics, 
including risperidone, whereas results from case 
descriptions suggest that some atypical antipsychotics 
may be effective in reducing psychotic symptoms 
(Table 1). In case of Parkinsonian symptoms, some 
alleviation may be achieved upon treatment with L-
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dopa [57]. Most important, however, is a contextual 
psychological treatment that guaranties a safe, well 
known and structured environment, where possible 
directed at the impaired capacity to estimate intentions, 
emotions and behaviours of others [58, 59]. 
Distal 22q11 Microdeletionsyndrome (OMIM: 
611867) 
Here, the microdeletion is located distal to the 
common ~ 3Mb deletion as seen in 22q11DS. In 
contrast to the classical 22q11.2 microdeletion 
syndrome, facial dysmorphisms, cognitive and 
behavioural problems as well as psychiatric symptoms 
are typically less pronounced. With respect to somatic 
comorbidity, a wide range of congenital heart defects 
have been described extending the cardiac 
phenotypical range [60]. When the 22q11 distal 
deletion includes the SMARCB1 gene, an increased 
risk is present on the development of malignant 
rhabdoid tumor [61]. In some patients with distal 22q11 
microdeletion syndrome, symptoms from the anxiety 
cluster have been reported that may be 
pathophysiologically connected to the absence of the 
MAPK1 gene which is accompanied by a disordered 
neurobiological stress homeostasis. Treatment with an 
antidepressant such as citalopram may then lead to full 
remission of anxiety symptoms [62].  
17q21.31 Microdeletion Syndrome (Koolen-De Vries 
Syndrome; OMIM:610443) 
This microdeletion syndrome was first described 
genotypically by Koolen and colleagues and thought to 
be caused by an interstitial deletion in 17q21.31, 
comprising the MAPT gene. Subsequently, they 
reported the somatic abnormalities of which facial 
dysmorphisms, central nervous system anomalies, and 
congenital heart and/or kidney defects are most 
prominent [63]. Nowadays, the KANSL1 gene 
(17q31.31) has been demonstrated to be causative for 
the phenotype [64]. Given its monogenic aetiology, the 
syndrome was re-termed as Koolen-De Vries 
syndrome. With respect to the behavioural phenotype, 
in addition to intellectual disability, an amiable, friendly 
disposition was described [65]. Cognitive phenotyping 
of a small number of patients disclosed hypersociability 
accompanied by high levels of frustration tolerance to 
Table 1: Atypical Psychosis in Patients with del22q11: Putative Treatment Strategies  
Case report Sex/Age 
(y;m) 
Antipsychotic Daily 
Dose 
Co-Medication Results Remarks 
Gladston & Clarke 
(2005) 
[122] 
male/32 clozapine 300mg sodium valproate 
1200mg 
Marked reduction of 
psychotic symptoms 
Constipation and hypersalivation; 
myoclonic epilepsy without 
history of epilepsy 
Briegel (2007) 
[123] 
male/12;10 clozapine 450mg none Significant reduction 
of psychotic 
symptoms 
No improvement and severe 
extrapyramidal side-effects on 
haloperidol; clozapine stopped 
because of seizures 
Krahn et al. (1998) 
[124] 
male/30 clozapine 125mg (?)  phenytoin 200mg Medically stable 
condition 
No effect of and extrapyramidal 
side effects on fluphenazine; 
Yacoub & Aybar 
(2007) [125] 
female/25 clozapine 75mg sodium valproate 
750mg 
Full recovery of 
psychosis 
Initially seizures; no effect of 
olanzapine, aripiprazole, 
ziprasidone and perphenzaine 
Gagliano & Masi 
(2009) [126] 
female/7;1 aripiprazole 15mg 
plus clozapine 
150mg 
none Dramatic 
improvement of 
psychotic symptoms 
Nonresponsive to risperidone 
and aripiprazole monotherapy 
Sporn et al. (2004) 
( four cases) [127] 
unknown clozapine or 
olanzapine or 
quetiapine 
none Good clinical 
response 
Epileptiform EEG 
changes/seizures in three 
patients 
Müller & Fellgiebel 
(2008) 
[128] 
female/41 quetiapine 300-
400mg 
none Free of psychotic 
symptoms 
No side-effects 
Lin et al. (2010) 
[129] 
female/16 aripiprazole 10-
25mg 
calcium 1500mg 
plus calciferol 
0,25μg 
Free of psychotic 
symptoms 
Hypoparathyroidism; no side-
effects 
Carandang & 
Scholten (2007) 
[130] 
male/17 metyrosine 1000mg*  none Significant functional 
improvement 
No response on aripiprazole 
Note. * Competitive inhibitor of the enzyme tyrosinehydroxylase. 
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form the core of the neuropsychological phenotype 
[66]. Such a profile is to some extent comparable to 
that observed in Angelman syndrome and Williams 
syndrome and therefore, Koolen-De Vries syndrome 
should be included in their differential diagnosis.  
9q Subtelomere Deletion Syndrome (Kleefstra 
Syndrome; OMIM:610253) 
Kleefstra syndrome, originally termed 9q 
subtelomeric deletion syndrome, is in the majority of 
cases caused by a microdeletion in chromosomal 
region 9q34.3 [67] and in some by a mutation in the 
euchromatin histione methyltransferase 1 (EHMT1) 
gene [68, 69]. In all cases, however, loss of function of 
the EHMT1 gene is the causative factor. Its core 
phenotype comprises developmental delay/intellectual 
disability, hypotonia and distinct facial dysmorphisms, 
and may be associated with congenital heart and/or 
renal defects and epilepsy [70]. The behavioural 
phenotype of Kleefstra syndrome constitutes particular 
sleep disturbances, characterized by frequent 
awakenings and daytime sleepiness, and marked loss 
of activity [71]. With respect to course, it has been 
demonstrated that the severity of behavioural and 
motor deficiencies such as fixed flexure of arms and 
hands, increases over time and debutes after 
adolescence, pointing at a neurodegenerative pattern 
[72]. Over time, reduced motor activity, markedly 
restricted social interactions and minimal to absent 
behavioural initiative and emotional responsivity 
become most prominent, a cluster of symptoms that 
meets the criteria for the syndrome of apathy. This 
constellation of motor and emotional features may 
easily be misdiagnosed as either mood disorder [73] or 
catatonia [74]. It is understandable, therefore, that 
treatment with antidepressants or benzodiazepines 
cannot be effective. 
Beta-Propeller Protein Associated Neurodegen-
eration (BPAN; OMIM:300894) 
Neurodegeneration with brain iron accumulation 
(NBIA) comprises an array of progressive brain 
disorders presenting with neurological and psychiatric 
symptoms, sometimes accompanied by intellectual 
impairment and behavioural problems. Originally, the 
neuropathologists Hallervorden and Spatz described in 
1922 a typical phenotype characterized neurologically 
by movement disorders and pathologically by iron 
accumulation in the basal ganglia [75]. Since the late 
sixties of the past century, several progressive 
movement disorders with iron excess in different parts 
of the basal ganglia have been described that, with the 
introduction of brain magnetic resonance imaging 
techniques, could be further differentiated and can 
clinically be subdivided into two major groups: early 
onset / rapid deterioration, and late onset / slow 
deterioration [76].  
NBIA has to be suspected when brain MRI findings 
point at abnormal iron accumulation in the basal 
ganglia, particularly globus pallidus or substantia nigra, 
in combination with dystonia and Parkinsonism. Until 
recently, seven genetic types of NBIA could be 
identified, of which six are inherited in an autosomal 
recessive and one in an autosomal dominant way. 
Recently, Kruer and co-workers [77] described a 
novel NBIA showing an additional specific 
neuroimaging pattern in the substantia nigra together 
with global cerebral atrophy. Clinically, this NBIA is 
different than the other types and does not fit within the 
aforementioned subdivision into two groups. Here, the 
disease starts with early childhood intellectual 
impairment that remains static during several decades 
after which progressive cognitive decline occurs and 
neurological symptoms emerge, especially dystonia 
and Parkinsonism, and therefore termed Static 
Encephalopathy of childhood with Neurodegeneration 
in Adulthood (SENDA). Shortly thereafter, it became 
clear that this condition is caused by de novo 
heterozygous mutations in the WD repeat-containing 
protein 45 (WDR45) gene (OMIM:300526) located in 
Xp11.23 [78]. Given the specific properties of the 
protein encoded by WDR45, the name Beta-propeller 
Protein Associated Neurodegeneration (BPAN) was 
suggested to be most appropriate [79, 80]. Nowadays, 
it has been demonstrated that the clinical phenotype of 
this X-linked dominant NBIA disorder is in its early 
phase characterized by developmental delay and 
intellectual disability, and frequently associated with 
epileptic seizures. The second phase, generally 
starting in the second or third decade, is clinically 
dominated by progressive cognitive and motor 
deterioration with prominent dystonia and Parkinsonian 
symptoms, ultimately leading to dementia [81].  
Since in the beginning of the second phase, 
symptoms from the apathetic/autistic and anxiety/mood 
spectrum may be present, these can be wrongly 
diagnosed as a depressive disorder instead of 
contingent upon the symptom profile in patients with 
early stages of Parkinson’s disease. Therefore, 
antidepressants will not be effective. Treatment with 
Levodopa/carbidopa in patients with BPAN may result 
in temporal or partial effects on motor function [79, 82]. 
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Lysosomal Disease 
Although metabolic disorders generally debute at 
early age, some of these may start in late adolescence 
or early adulthood. In case of lysosomal disease such 
as Niemann-Pick type C (mutation NPC1 gene; 
18q11.2 [OMIM:257220] or NPC2 gene; 14q24.3 
[OMIM:607625]) a late onset presentation may, apart 
from pre-existing (mild) developmental delay, manifest 
firstly with a schizophrenia-like psychosis with or 
without catatonic symptoms [83, 84]. Another example 
is mucopolysaccharidosis type IIIB (MPSIIIB; Sanfilippo 
B; OMIM: 252920) that is caused by a mutation in the 
NAGLU gene (17q21.1; OMIM: 609701) resulting in a 
deficiency of N-acetyl--D-glucosaminidase. MPSIIIB is 
characterized by later onset developmental delay 
followed by slow progressive dementia starting from 
the fourth decade [85, 86]. These two lysosomal 
diseases do not present with specific dysmorphisms 
and can therefore be easily misdiagnosed as either late 
onset schizophrenia or early onset Alzheimer’s 
dementia. 
DISCUSSION AND CONCLUSIONS 
In this paper, the difficulties in the diagnostic 
process and the choice for rational treatment strategies 
in intellectually disabled patients with challenging 
behaviours and/or neuropsychiatric symptoms are 
presented. Because of the regular co-occurrence of 
psychiatric and/or neurological symptoms in this group 
of patients, some examples of genetic syndromes are 
given that are characterized by a psychopathological 
and/or neurological phenotype. 
As mentioned previously, psychiatric symptoms 
may originate in the context of a traditional psychiatric 
disorder that presents frequently with an atypical 
symptomatology like disinhibited behaviours and/or 
self-injuries, or as part of a so called 
psychopathological phenotype. Moreover, a psychiatric 
disorder may be related to an underlying 
somatic/neurological disease. In addition, both 
challenging behaviours and psychiatric symptoms may 
be drug-related (e.g. antiepileptics and psychotropics). 
Finally, disinhibited behaviours frequently arise as a 
result of environmental factors.  
As known for several decades, both depressive 
diseases and anxiety disorders frequently manifest with 
either pronounced irritability, perseverative/compulsive 
behaviours and motoric signs, or an exacerbation of 
challenging behaviours, and are therefore often 
symptomatically treated with antipsychotics instead of 
with antidepressants [87-89]. Concerning antidepre-
ssant medications, it has been shown that these 
compounds, particularly SSRIs, reduce symptoms in 
only half of the patients [90]. When depressive 
symptoms occur in the context of a so called unstable 
mood disorder or a bipolar affective disorder, treatment 
with antiepileptics, preferably valproic acid is the 
method of choice [45, 91]. 
By using categorical diagnostic systems, 
repetitive/stereotyped and/or disinhibited behaviours 
may easily meet the criteria for autism spectrum 
disorder (ASD) or attention deficit hyperactivity disorder 
(ADHD). Although some beneficial effects of atypical 
antipsychotics, especially risperidone and aripiprazole, 
on autistic symptoms (i.e., irritability and repetition) 
have been reported [92, 93], systematic reviews could 
not substantiate this claim for either risperidone or 
aripiprazole [94, 95]. This holds, a fortiori, for ADHD 
[96]. As reported recently, for the treatment of ADHD in 
intellectually disabled patients in whom anxiety 
disorders or severe tics are frequently also present, the 
selective noradrenaline reuptake inhibitor amoxetine 
should be preferred [97]. 
In case of challenging behaviours in general, 
prescription of neuroleptics, particularly second 
generation antipsychotics, has been demonstrated to 
be only marginally effective [98, 99]. It should be 
stressed that such treatments are regularly 
accompanied by unwanted side effects especially 
significant weight gain and the development over time 
of dislipidemia and/or diabetes mellitus, subsumed 
under the term metabolic syndrome [100,101].  
With respect to psychopathological phenotypes, it 
has become obvious that certain genetic syndromes 
can be characterized by their specific psychiatric or 
neuropsychological profile like e.g. 22q11.2 micro-
deletion syndrome and Koolen-De Vries syndrome. In 
those cases, routine pharmacological treatments are 
generally ineffective. For some syndromes, such as 
Prader-Willi syndrome, a circumscript subset of 
recurrent affective/psychotic symptoms may occur, 
especially when the aetiology is a maternal uniparental 
disomy. These patients develop, starting in their late 
adolescence, a subacute polymorphous psychosis with 
a symptom profile that meets the criteria for cycloid 
psychosis [102-106]. In some cases, an increase of 
psychomotor symptoms dominates the psychotic-
syndrome resembling catatonia [107]. After several 
relapses with generally full recovery, course and 
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symptomatology overlap that of a bipolar affective 
disorder and the psychosis should therefore be treated 
primarily with mood stabilizing agents e.g. Lithium or 
valproic acid [54, 108]. 
As can be inferred from the aforementioned, the 
contribution of psychopharmacological agents to the 
reduction of ID-related behavioural problems and 
psychiatric symptoms is relatively poor. This is affirmed 
by the results of the only placebo controlled study with 
haloperidol and risperidone showing the largest effect 
on challenging behaviours of placebo [109]. Further-
more, controlled discontinuation of antipsychotics 
prescribed for behavioural symptoms over multiple 
years has demonstrated improved behavioural 
functioning and amelioration of metabolic parameters 
[110-112]. In fact, challenging behaviours may even be 
the first and only manifestation of motor or autonomic 
side effects of psychotropics e.g. acathisia [42]. 
Given the frequent polymedication in ID patients 
and the absence of reliable data on plasma 
concentration-effect relationship of psychotropics in this 
group of patients, it is highly recommended to measure 
the plasma concentration of antipsychotics, antidepres-
sants and antiepileptics and, if applicable, their active 
or toxic metabolites. As mentioned before, the latter is 
of special importance since the clinical impact is 
influenced by the genetically determined capacity of the 
cytochrome P450 (CYP) isoenzym system, in particular 
CYPs 2D6, 2C9 and 2C19. It should be noticed that 
CYP 2D6 and CYP 2C19 are responsible for 
metabolizing a range of antipsychotics and antidepres-
sants, and polymorphism for these enzymes may result 
in ultra rapid or poor biotransformation which, in turn, 
defines effect and toxicity [40, 113, 114]. CYP-
genotyping prior to the prescription of psychotropics 
especially in case of co-medication with antiepileptics 
has therefore always to be considered.  
Since challenging behaviours are essentially 
dependent on environmental variables and no rational 
psychopharmacological treatment is available for such 
behaviours, again, functional re-analysis of the 
behavioural history is needed in order to define 
appropriate psychological and/or behavioural interven-
tions. To this end, several treatment programs based 
on operant learning and cognitive models with 
documented efficacy can be employed such as 
differential reinforcement strategies (e.g. to reduce 
inappropriate vocalisations), low level problem solving, 
assertiveness and goal management training [115-
118]. In certain genetic disorders like Noonan 
syndrome and Turner syndrome, specific impairments 
in affective information processing and social 
interaction can be identified and may be modulated by 
means of targeted social-cognitive training [119-121]. 
In conclusion, from the here presented data, it has 
become obvious that a careful investigation and 
analysis of abnormal behaviours in patients with ID is 
essential for establishing an appropriate diagnostic 
process leading to a diagnostic hypothesis with a 
subsequent, individually targeted, treatment program 
including regular evaluation of effectiveness and 
potential side effects. This holds particularly for some 
genetic syndromes that may be accompanied with a 
specific set of behavioural, psychiatric or neurological 
symptoms that may be of major clinical relevance for 
prognosis. Albeit that psychotropics may be effective in 
the treatment of psychiatric symptoms and useful for 
alleviating challenging behaviours in patients with 
intellectual disabilities, behavioural interventions have 
to be employed where possible, and effectiveness as 
well as side effects of psychopharmacological 
interventions should be monitored regularly.  
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